With significant upside potential, Viridian Therapeutics, Inc. (NASDAQ:VRDN) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. On November 6, 2025, RBC …
RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results
view original post